title: Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk.
abstract: The worldwide burden of cardiovascular disease is growing. In addition to lifestyle changes, pharmacologic agents that can modify cardiovascular disease processes have the potential to reduce cardiovascular events. Antihypertensive agents are widely used to reduce the risk of cardiovascular events partly beyond that of blood pressure-lowering. In particular, the angiotensin II receptor blockers (ARBs), which antagonize the vasoconstrictive and proinflammatory/pro-proliferative effects of angiotensin II, have been shown to be cardio vascularly protective and well tolerated. Although the eight currently available ARBs are all indicated for the treatment of hypertension, they have partly different pharmacology, and their pharmacokinetic and pharmacodynamic properties differ. ARB trials for reduction of cardiovascular risk can be broadly categorized into those in patients with/without hypertension and additional risk factors, in patients with evidence of cardiovascular disease, and in patients with severe cardiovascular disease, such as heart failure. These differences have led to their indications in different populations. For hypertensive patients with left ventricular hypertrophy, losartan was approved to have an indication for stroke prevention, while for most patients at high-risk for cardiovascular events, telmisartan is an appropriate therapy because it has a cardiovascular preventive indication. Other ARBs are indicated for narrowly defined high-risk patients, such as those with hypertension or heart failure. Although in one analysis a possible link between ARBs and increased risks of cancer has surfaced, several meta-analyses, using the most comprehensive data available, have found no link between any ARB, or the class as a whole, and cancer. Most recently, the US Food and Drug Administration completed a review of the potential risk of cancer and concluded that treatment with an ARB medication does not increase the risk of developing cancer. This review discusses the clinical evidence supporting the different indications for each of the ARBs and the outstanding safety of this drug class.
authors.affiliation: Cardiometabolic Center, Department of Internal Medicine, St Imre Hospital, Budapest, Hungary. hunghyp@t-online.hu
authors.forename: Csaba
authors.initials: C
authors.lastname: Farsang
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D018579:Patient Selection; D011322:Primary Prevention / Q000379:methods*; D012084:Renin-Angiotensin System / Q000187:drug effects; D055502:Secondary Prevention / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents
references.citation: Lancet. 2009 Nov 28;374(9704):1840-8
references.pmid: 19922995
references.citation: Lancet. 2005 Sep 10-16;366(9489):907-13
references.pmid: 16154017
references.citation: Hypertension. 2011 Mar;57(3):413-20
references.pmid: 21282560
references.citation: Circulation. 2006 Aug 22;114(8):838-54
references.pmid: 16923768
references.citation: Lancet. 2000 Feb 19;355(9204):637-45
references.pmid: 10696996
references.citation: Arch Intern Med. 2007 Oct 8;167(18):1930-6
references.pmid: 17923591
references.citation: J Int Med Res. 2009 Nov-Dec;37(6):1662-79
references.pmid: 20146864
references.citation: Int J Clin Pract. 2006 Mar;60(3):315-20
references.pmid: 16494647
references.citation: Adv Ther. 2005 Jan-Feb;22(1):32-43
references.pmid: 15943220
references.citation: Am J Hypertens. 2011 Nov;24(11):1181-6
references.pmid: 21938071
references.citation: J Hypertens. 2005 Dec;23(12):2113-8
references.pmid: 16269950
references.citation: Heart. 2006 Oct;92(10):1384-9
references.pmid: 16702172
references.citation: Drug Saf. 2003;26(10):707-20
references.pmid: 12862505
references.citation: J Hypertens. 2007 Jul;25(7):1327-36
references.pmid: 17563549
references.citation: Am J Med. 2009 Mar;122(3):290-300
references.pmid: 19272490
references.citation: Chest. 2006 Jan;129(1 Suppl):169S-173S
references.pmid: 16428706
references.citation: Vasc Health Risk Manag. 2011;7:297-313
references.pmid: 21633727
references.citation: Lancet Oncol. 2011 Jan;12(1):65-82
references.pmid: 21123111
references.citation: J Pharmacol Exp Ther. 2011 Mar;336(3):801-8
references.pmid: 21123673
references.citation: Clin Ther. 2008 Apr;30(4):587-604
references.pmid: 18498909
references.citation: Hypertension. 2008 Jun;51(6):1624-30
references.pmid: 18413488
references.citation: N Engl J Med. 2008 Sep 18;359(12):1225-37
references.pmid: 18753639
references.citation: BMJ. 2003 Jun 28;326(7404):1427
references.pmid: 12829555
references.citation: J Clin Pharmacol. 2000 Dec;40(12 Pt 1):1338-46
references.pmid: 11185632
references.citation: Ann Intern Med. 2008 Jan 1;148(1):16-29
references.pmid: 17984484
references.citation: Hypertension. 2003 Oct;42(4):542-7
references.pmid: 12963679
references.citation: J Clin Hypertens (Greenwich). 2011 Feb;13(2):81-8
references.pmid: 21272195
references.citation: High Blood Press Cardiovasc Prev. 2011 Mar 1;18(1):37-40
references.pmid: 21612311
references.citation: N Engl J Med. 2004 Nov 4;351(19):1952-61
references.pmid: 15516696
references.citation: Hypertension. 2008 Jun;51(6):1465-7
references.pmid: 18413486
references.citation: Am J Hypertens. 2008 Aug;21(8):852-9
references.pmid: 18535538
references.citation: Lancet. 2007 Apr 7;369(9568):1208-19
references.pmid: 17416265
references.citation: J Clin Hypertens (Greenwich). 2009 Apr;11(4):207-13
references.pmid: 19614805
references.citation: Ann Intern Med. 2004 Nov 2;141(9):693-704
references.pmid: 15520426
references.citation: N Engl J Med. 2001 Sep 20;345(12):851-60
references.pmid: 11565517
references.citation: Lancet. 2000 May 6;355(9215):1582-7
references.pmid: 10821361
references.citation: J Cardiovasc Pharmacol. 2011 Aug;58(2):143-8
references.pmid: 21558880
references.citation: Cardiol Rev. 2011 Mar-Apr;19(2):90-4
references.pmid: 21285669
references.citation: Lancet. 2003 Sep 6;362(9386):759-66
references.pmid: 13678868
references.citation: Postgrad Med. 2011 Jan;123(1):80-7
references.pmid: 21293087
references.citation: Circulation. 2010 Feb 23;121(7):e46-e215
references.pmid: 20019324
references.citation: Lancet. 2002 Mar 23;359(9311):995-1003
references.pmid: 11937178
references.citation: BMJ. 2009 May 19;338:b1665
references.pmid: 19454737
references.citation: Hypertens Res. 2008 May;31(5):921-9
references.pmid: 18712048
references.citation: Eur Heart J. 2005 Nov;26(22):2381-6
references.pmid: 16081468
references.citation: J Am Coll Cardiol. 2010 Nov 16;56(21):1701-8
references.pmid: 21070920
references.citation: Lancet. 2003 Sep 6;362(9386):782-8
references.pmid: 13678872
references.citation: N Engl J Med. 2001 Sep 20;345(12):870-8
references.pmid: 11565519
references.citation: Vasc Health Risk Manag. 2007;3(5):579-85
references.pmid: 18078009
references.citation: J Hum Hypertens. 2002 May;16 Suppl 2:S13-6
references.pmid: 11967728
references.citation: N Engl J Med. 2003 Nov 13;349(20):1893-906
references.pmid: 14610160
references.citation: Curr Med Res Opin. 2007 Nov;23 Suppl 5:S1-3
references.pmid: 18093407
references.citation: N Engl J Med. 2001 Dec 6;345(23):1667-75
references.pmid: 11759645
references.citation: Lancet Oncol. 2010 Jul;11(7):627-36
references.pmid: 20542468
references.citation: J Hypertens. 2011 Apr;29(4):623-35
references.pmid: 21358417
references.citation: Lancet. 2004 Jun 19;363(9426):2022-31
references.pmid: 15207952
references.citation: N Engl J Med. 2001 Sep 20;345(12):861-9
references.pmid: 11565518
references.citation: J Hypertens. 2009 Nov;27(11):2121-58
references.pmid: 19838131
references.citation: Lancet. 2010 Apr 3;375(9721):1173-81
references.pmid: 20170948
references.citation: Eur J Heart Fail. 2004 Dec;6(7):937-45
references.pmid: 15556056
references.citation: J Clin Hypertens (Greenwich). 2007 Mar;9(3):187-95
references.pmid: 17341994
references.citation: Lancet. 2005 Sep 10-16;366(9489):895-906
references.pmid: 16154016
references.citation: Circulation. 2006 Dec 19;114(25):2871-91
references.pmid: 17179035
references.citation: J Am Board Fam Med. 2009 Nov-Dec;22(6):686-97
references.pmid: 19897698
references.citation: Curr Med Res Opin. 2004 Mar;20(3):369-79
references.pmid: 15025846
references.citation: Hypertension. 2003 Dec;42(6):1206-52
references.pmid: 14656957
references.citation: J Clin Hypertens (Greenwich). 2001 Sep-Oct;3(5):283-91, 318
references.pmid: 11588406
references.citation: N Engl J Med. 2011 Mar 10;364(10):907-17
references.pmid: 21388309
references.citation: Eur Heart J. 2007 Jun;28(12):1462-536
references.pmid: 17562668
references.citation: Hypertension. 2004 May;43(5):993-1002
references.pmid: 15007034
references.citation: Hypertension. 2005 Jan;45(1):46-52
references.pmid: 15583076
references.citation: J Hypertens. 2008 Apr;26(4):819-24
references.pmid: 18327094
references.citation: Peptides. 2005 Aug;26(8):1401-9
references.pmid: 16042980
references.citation: Lancet. 2002 Sep 7;360(9335):752-60
references.pmid: 12241832
references.citation: J Card Fail. 2010 Dec;16(12):964-70
references.pmid: 21111986
references.citation: Am J Hypertens. 2008 Oct;21(10):1157-62
references.pmid: 18670416
references.citation: Circulation. 2006 Aug 22;114(8):855-60
references.pmid: 16923769
references.citation: Mediators Inflamm. 2009;2009:752406
references.pmid: 19390623
references.citation: Nephrol Dial Transplant. 2008 Oct;23(10):3174-83
references.pmid: 18450829
references.citation: Eur Heart J. 2006 Jul;27(13):1610-9
references.pmid: 16495286
references.citation: PLoS Med. 2006 Nov;3(11):e442
references.pmid: 17132052
references.citation: Lancet Oncol. 2010 Sep;11(9):820-1; author reply 821-2
references.pmid: 20816379
references.citation: J Med Chem. 1993 Dec 10;36(25):4040-51
references.pmid: 8258826
references.citation: Kidney Int. 2004 Mar;65(3):1041-9
references.pmid: 14871425
references.citation: Circulation. 2009 Feb 3;119(4):530-7
references.pmid: 19153265
references.citation: J Hum Hypertens. 2000 Apr;14 Suppl 1:S73-86
references.pmid: 10854085
references.citation: N Engl J Med. 2008 Apr 10;358(15):1547-59
references.pmid: 18378520
references.citation: J Renin Angiotensin Aldosterone Syst. 2000 Jun;1(2):147-50
references.pmid: 11967806
references.citation: N Engl J Med. 2000 Jan 20;342(3):145-53
references.pmid: 10639539
references.citation: N Engl J Med. 2008 Dec 4;359(23):2456-67
references.pmid: 19001508
references.citation: Lancet. 2000 Jan 22;355(9200):253-9
references.pmid: 10675071
references.citation: Eur Heart J. 2009 Oct;30(20):2461-9
references.pmid: 19723695
references.citation: Hypertens Res. 2005 May;28(5):385-407
references.pmid: 16156503
references.citation: Lancet. 2008 Sep 27;372(9644):1174-83
references.pmid: 18757085
references.citation: Am J Cardiovasc Drugs. 2005;5(1):41-50
references.pmid: 15631537
references.citation: Lancet. 2003 Sep 6;362(9386):777-81
references.pmid: 13678871
references.citation: Lancet. 2004 Nov 6-12;364(9446):1684-9
references.pmid: 15530629
references.citation: Kidney Int. 2008 Nov;74(9):1128-38
references.pmid: 18650791
references.citation: Lancet. 2007 Apr 28;369(9571):1431-1439
references.pmid: 17467513
references.citation: Postgrad Med. 2009 Mar;121(2):5-14
references.pmid: 19332958
references.citation: Circulation. 2006 Dec 19;114(25):2850-70
references.pmid: 17179034
references.citation: Diabetes Care. 2003 Mar;26(3):569-74
references.pmid: 12610003
references.citation: Nutr Hosp. 2010 Mar-Apr;25(2):275-9
references.pmid: 20449538
references.citation: N Engl J Med. 2002 Aug 22;347(8):621-2
references.pmid: 12192030
references.citation: J Eval Clin Pract. 2004 Nov;10(4):499-509
references.pmid: 15482412
references.citation: J Clin Hypertens (Greenwich). 2009 Feb;11(2):66-73
references.pmid: 19222670
references.citation: Kidney Int. 2008 Aug;74(3):364-9
references.pmid: 18496508
references.citation: Am J Cardiol. 2002 Jan 24;89(2A):3A-9A; discussion 10A
references.pmid: 11835903
references.citation: J Am Coll Cardiol. 2004 Sep 15;44(6):1175-80
references.pmid: 15364316
references.citation: Int J Clin Pharmacol Res. 2005;25(1):41-6
references.pmid: 15864875
references.citation: Vasc Health Risk Manag. 2009;5:1043-58
references.pmid: 20057897
references.citation: Clin Ther. 2011 Apr;33(4):456-64
references.pmid: 21635991
references.citation: BMJ. 2004 Nov 27;329(7477):1248-9
references.pmid: 15564232
references.citation: Stroke. 2003 Jul;34(7):1699-703
references.pmid: 12817109
references.citation: J Clin Hypertens (Greenwich). 2008 Mar;10(3):185-94
references.pmid: 18326958
references.citation: N Engl J Med. 2006 Jul 20;355(3):251-9
references.pmid: 16855265
references.citation: N Engl J Med. 2008 Dec 4;359(23):2417-28
references.pmid: 19052124